Skip to main content

Table 2 The outcomes of CAR-T therapy with different costimulatory molecules for CLL patients in published trials

From: Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia

Signal Target Study Number Preconditioning Source Cell dose ORR and CRR
CD28 CD19 2011.Brentjens 8 None (3) Autologous Without preconditioning: 1.2–3.0 × 107/kg ORR 1/7 (14.3%)
CRR 0/7 (0%)
Cyclophosphamide (5) With preconditioning: 0.4–1.0 × 107/kg One died before evaluation
2012.Kochenderfer 4 Fludarabine + cyclophosphamide (4) Autologous 0.3–2.8 × 107/kg ORR 3/4 (75.0%)
CRR 1/4 (25.0%)
2013.Cruz 4 None Allogeneic 1.5–12 × 107/m2 ORR 1/4 (25.0%)
CRR 0/4 (0%)
2015.Kochenderfer 4 Fludarabine + cyclophosphamide (4) Autologous 1–4 × 106/kg ORR 4/4 (100%)
CRR 3/4 (75.0%)
2015.Kochenderfer
2016.Brudno
5 None Allogeneic 0.4–3.1 × 106/kg ORR 2/5 (40.0%)
CRR 1/5 (20.0%)
2018.Geyer 8 Cyclophosphamide (8) Autologous 3 × 106/kg, 1 × 107/kg
3 × 107/kg
ORR 2/8 (25.0%)
CRR 2/8 (25.0%)
κ 2016. Ramos 2 None Autologous 9.1 × 107/m2 ORR 0/2 (0%)
1.6 × 108/m2 CRR 0/2 (0%)
CD137 CD19 2011.Kalos 14 Bendamustine (6) Autologous 0.14–11 × 108 ORR 8/14 (57.1%)
2011.Porter Fludarabine/cyclophosphamide (3) CRR 4/14 (28.6%)
2015.Porter Pentostatin/cyclophosphamide (5)
2017.Turtle 24 Fludarabine + cyclophosphamide (21) Autologous 2 × 105/kg, 2 × 106/kg ORR 16/23 (69.6%)
Fludarabine (2) CRR 4/23 (17.4%)
Cyclophosphamide (1) 2 × 107/kg One died before evaluation
  1. Abbreviations: ORR overall response rate, CRR complete remission rate